Chris Lord

 Chris Lord
Chris Lord
Team Leader and Reader in Cancer Genomics and Therapeutics
Institute of Cancer Research

Presentations at Drug Discovery 2015

Wed2  Sep03:30pm(30 mins)
The Application of Synthetic Lethality to Cancer Treatment

Session: Target Identification & Validation
Room: To be announced

Profile of Chris Lord

Dr. Chris Lord is a Team Leader and Reader in Cancer Genomics and Therapeutics at the Institute of Cancer Research, London. Much of the focus of his work is in exploiting genetic concepts such as synthetic lethality and functional genomics approaches to understand the behaviour of tumour cells. The ultimate aim of this work is to use this information to design novel ways to treat the disease. In recent years Dr. Lord's Gene Function Team at the ICR have used these approaches to understand how PARP inhibitors might be used to treat cancer and to develop novel drugs such as Tankyrase inhibitors. In addition, the laboratory has focussed on identifying and validating novel targets for use in breast cancer as well as dissecting the genetic control of drug sensitivity and drug resistance in this disease. Dr. Lord completed his DPhil in 1997, working on complex disease genetics at the Wellcome Trust Centre for Human Genetics, University of Oxford. After a post-doctoral position at the CIMR, University of Cambridge, he joined the ICR in 2000, becoming a Reader in 2014.


Poster Presenter
Dr Fiona Jeganathan
Post Doctoral Training Fellow
Institute of Cancer Research
Mark Stubbs
Institute of Cancer Research
Please login to send a Private Message

Hosted By
The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Find us on Facebook Follow us on Twitter

Get the App
Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
iPhone App
Android App
Eventflo Home
copyright ELRIG, eventflo, Labhoo Ltd 2018